Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II dose-escalation and dose-expansion study of doxitinib mesylate tablets in EGFR-mutant advanced or metastatic non-small cell lung cancer
CTR20202112Phase 2Active
- Sponsor
- Genuine Biotech
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of doxitinib in non-small cell lung cancer (NSCLC), sponsored by Genuine Biotech. Started Oct 2022; status: active.
02
Drugs
doxitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20202112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202112.